2026-05-14 · ALMS
Alumis delivered a focused and productive first quarter, building on the Phase 3 clinical validation of envudeucitinib in moderate - to - severe plaque psoriasis and reinforcing the differentiated potential of maximal TYK2 inhibition
ALMSSEC EDGAR 8-K exhibit ↗